It was shown that oxygen–ozone immunoceutical therapy (3–5 cycles with 100–200 mL of 45 μg/mL O2-O3 mixture QD for 5 days) in fifty patients hospitalized with COVID-19 and acute respiratory disease syndrome (ARDS) significantly ameliorated major respiratory indexes, reduced levels of inflammatory markers, and ultimately reduced the number of patients needing intensive care unit (ICU) hospitalization (CRP, IL-6) [196]. This evidence concerns the gene IL6 and COVID-19.